Clinical trial

Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion

Name

MECRVO

Description

Treatment of macular edema secondary to central retinal vein occlusion is more effective with combined therapy of bevacizumab and triamcinolone than bevacizumab alone.

Trial arms

Trial start

2007-06-01

Estimated PCD

2007-06-01

Trial end

2008-03-01

Status

Terminated

Phase

Early phase I

Treatment

bevacizumab and triamcinolone

three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2

Size

Primary endpoint

Changes in Best corrected visual acuity and macular edema measured with OCT

Follow up to 3 , 6 and 12 months

Eligibility criteria

Inclusion Criteria: * Macular edema secondary to central retinal vein occlusion * BCVA worse than 20/40 * Central macular \>250 mc with OCT Exclusion Criteria: * Diabetic retinopathy or other retinopathy * Media opacity that does not allow following * steroid responder * diagnosed glaucoma or IOP \> 21 mmHg

Protocol

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE4'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 10, 'type': 'ACTUAL'}}

Updated at

2024-05-30

1 organization

1 product

2 indications

Organization

Asociación para Evitar la Ceguera en México

Product

Bevacizumab + Triamcinolone

Indication

Macular Edema

Indication

Central Retinal Vein Occlusion